– ETX301 nominated as a development candidate for post-amputation neuroma pain, with a planned IND submission in 2027 – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics, Inc.

FDA alignment achieved on pivotal study design supporting a planned Biologics License Application (BLA) submission 30-patient pivotal study initiated, evaluating seizure reduction and ...

I never thought smart home tech was for me. Maybe that’s because my introduction to it was largely centered around my friends incessantly yelling “Hey Google!” whenever they wanted a light turned on ...

All the Latest Game Footage and Images from Encode Encore! A charming, slice-of-life indie RPG where you earn some sweet cash by trying out various part-time jobs—all in the name of getting your girl ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech on track to start a pivotal study next year. The Californian company’s ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Adrienne Maxwell Adrienne Maxwell is an editor covering AV gear. Her specialty ...

U.S. hotel occupancy, average daily rate and revenue per available room each declined year over year in September, hotel analytics firm STR announced. U.S. ADR decreased 0.1 percent year over year to ...

STR and Tourism Economics yet again have downgraded their U.S. hotel forecast for both full-year 2025 and 2026, citing lower demand due in part to "unrelenting uncertainty and inflation," the ...

Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage R&D toward its Dravet syndrome program. The asset in question, dubbed ...